EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Role of 18 F‐florzolotau PET in diagnostic and therapeutic decision‐making for cognitive impairment

Jun Wang, Zi-Yi Wang, Shu-Fen Chen, Rong-Ze Wang, Ke-Liang Chen, Jia-Ying Lu, Jia-Wei Xin, Yu-Yuan Huang, Ming-Yu Wang, Fang Xie, Wei Cheng, Tzu-Chen Yen und 6 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Jun Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Fronti…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Cognitive Dysfunction, Carbolines, Clinical Decision-Making. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Innovation 2030 Major Projects, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The novel positron emission tomography (PET) tracer, 18 F‐florzolotau, enables in vivo visualization of tau pathology. METHODS We evaluated the diagnostic performance of disease‐specific spatial patterns of 18 F‐florzolotau PET imaging by visual read for tauopathies and its added value in diagnostic and therapeutic decision‐making in 1277 participants with cognitive complaints. RESULTS The disease‐specific spatial patterns of 18 F‐florzolotau PET imaging demonstrated high diagnostic accuracy in differentiating various tauopathies, with 96.0% for Alzheimer's disease, 94.4% for frontotemporal lobe degeneration, 93.7% for progressive supranuclear palsy, and 97.5% for corticobasal degeneration. Added to a standard diagnostic workup, 18 F‐florzolotau PET reading led to diagnostic revisions for 247 participants (19.3%), increased diagnostic confidence from 68.6% to 81.3%, and resulted in medication changes for 284 participants (22.2%). DISCUSSION Our data advocate for the strategic implementation of 18 F‐florzolotau PET in memory clinics, offering transformative potential for patient care and management. Highlights 18 F‐Florzolotau PET imaging presented disease‐specific spatial patterns for different tauopathies. The disease‐specific spatial patterns of 18 F‐florzolotau positron emission tomography (PET) imaging exhibited high diagnostic accuracy in differentiating various tauopathies. Integration of 18 F‐florzolotau PET imaging modality to a standard diagnostic workup significantly enhanced diagnostic confidence, enabled diagnostic revisions, and informed adjustments to treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyCognitive DysfunctionCarbolinesClinical Decision-MakingTauopathiesHumansMaleFemaleAgedAlzheimer DiseaseMiddle AgedRadiopharmaceuticalsBrainSupranuclear Palsy, ProgressiveAged, 80 and over

Stichwörter der Autor:innen

18F‐Florzolotau PETdementiadiagnosistauopathy

Substanzen

CarbolinesRadiopharmaceuticals7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole

Autor:innen und Institutionen

  • Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan Universi…
  • Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.
  • Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China.
  • Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University, Fuzhou, China.
  • Departments of Neurology, Weifang People's Hospital, Weifang, Shandong, China.

Förderung

  • Science and Technology Innovation 2030 Major Projects
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Wang, J., Wang, Z. Y., Chen, S. F., Wang, R. Z., Chen, K. L., Lu, J. Y., Xin, J. W., Huang, Y. Y., Wang, M. Y., Xie, F., Cheng, W., Yen, T. C., Wischik, C. M., Cui, M., Zuo, C. T., Zhao, Q. H., Wang, Y. J., & Yu, J. T. (2025). Role of 18 F‐florzolotau PET in diagnostic and therapeutic decision‐making for cognitive impairment. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70563

Vancouver

Wang J, Wang ZY, Chen SF, Wang RZ, Chen KL, Lu JY, et al. Role of 18 F‐florzolotau PET in diagnostic and therapeutic decision‐making for cognitive impairment. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70563

BibTeX
@article{Wang2025,
  author = {Wang, Jun and Wang, Zi-Yi and Chen, Shu-Fen and Wang, Rong-Ze and Chen, Ke-Liang and Lu, Jia-Ying and Xin, Jia-Wei and Huang, Yu-Yuan and Wang, Ming-Yu and Xie, Fang and Cheng, Wei and Yen, Tzu-Chen and Wischik, Claude M and Cui, Mei and Zuo, Chuan-Tao and Zhao, Qian-Hua and Wang, Yan-Jiang and Yu, Jin-Tai},
  title = {Role of 18 F‐florzolotau PET in diagnostic and therapeutic decision‐making for cognitive impairment},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70563}
}
Kostenlos starten →